REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $27.50.

Several research analysts have recently weighed in on the company. Wall Street Zen cut REGENXBIO from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Chardan Capital decreased their price target on REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. The Goldman Sachs Group decreased their price target on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Barclays assumed coverage on REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price target for the company. Finally, HC Wainwright decreased their price target on REGENXBIO from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, March 9th.

Insider Buying and Selling at REGENXBIO

In other news, insider Steve Pakola sold 5,124 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $10.35, for a total value of $53,033.40. Following the completion of the transaction, the insider owned 247,926 shares in the company, valued at $2,566,034.10. The trade was a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.79% of the stock is owned by corporate insiders.

Institutional Trading of REGENXBIO

Large investors have recently modified their holdings of the company. State of Alaska Department of Revenue bought a new stake in shares of REGENXBIO in the third quarter worth $25,000. Aquatic Capital Management LLC bought a new stake in shares of REGENXBIO in the third quarter worth $37,000. Jones Financial Companies Lllp grew its holdings in shares of REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares during the period. Captrust Financial Advisors bought a new stake in shares of REGENXBIO in the second quarter worth $85,000. Finally, Prudential Financial Inc. bought a new stake in shares of REGENXBIO in the second quarter worth $87,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Trading Up 1.7%

Shares of NASDAQ:RGNX opened at $9.12 on Friday. The stock has a fifty day simple moving average of $8.75 and a two-hundred day simple moving average of $11.19. The stock has a market capitalization of $470.77 million, a price-to-earnings ratio of -2.43 and a beta of 1.12. REGENXBIO has a 12-month low of $6.89 and a 12-month high of $16.19.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.29). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The business had revenue of $30.34 million during the quarter, compared to analysts’ expectations of $45.48 million. As a group, equities research analysts predict that REGENXBIO will post -2.34 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.